Literature DB >> 12413317

Intraductal papillary-mucinous tumors of the pancreas: predictive criteria of malignancy according to pathological examination of 53 cases.

Pierre Bernard1, Jean-Yves Scoazec, Madeleine Joubert, Xavier Kahn, Joël Le Borgne, Françoise Berger, Christian Partensky.   

Abstract

BACKGROUND: One of the main problems in the management and treatment of intraductal papillary-mucinous tumors is the lack of a reliable predictive factor for malignancy. HYPOTHESIS: Surgical treatment could be adapted to macroscopic criteria (presence of mural nodules and diameter of the pancreatic duct and of the lesion) or to tumor location (main duct, branch duct, or combined lesions) associated with benign or malignant forms.
DESIGN: Retrospective study.
SETTING: Two university and tertiary referral centers. PATIENTS: Fifty-three consecutive patients who underwent pancreatic resection for intraductal papillary-mucinous tumors between January 1, 1985, and December 31, 2000.
RESULTS: Macroscopic analyses of tumors showed 6 main duct lesions, 12 branch duct lesions, and 35 combined lesions. A carcinoma was present in 33 cases (62%): 22 (41%) were invasive and 11 (21%) were noninvasive; 9 (17%) were borderline tumors and 11 (21%) were benign. Carcinoma and invasive carcinoma forms were less frequent in branch duct lesions (P<.001 and P =.009, respectively). Mural nodules were more frequent in carcinomas (P =.006) and invasive carcinomas (P<.001), with a positive predictive value of malignancy of 81%. The diameter of lesions (branch duct lesion > or =30 mm) or main duct (main pancreatic duct > or =15 mm in combined or main pancreatic duct lesions) did not correlate with malignancy.
CONCLUSIONS: No carcinoma occurred in branch duct types smaller than 30 mm without mural nodules. Limited resection may be appropriate only in this type of tumor.

Entities:  

Mesh:

Year:  2002        PMID: 12413317     DOI: 10.1001/archsurg.137.11.1274

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  32 in total

1.  Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution.

Authors:  Dae Wook Hwang; Jin-Young Jang; Seung Eun Lee; Chang-Sup Lim; Kuhn Uk Lee; Sun-Whe Kim
Journal:  Langenbecks Arch Surg       Date:  2010-07-18       Impact factor: 3.445

Review 2.  [Intraductal papillary mucinous neoplasia: which findings support observation?].

Authors:  J Mayerle; M Kraft; P Menges; P Simon; J Ringel; L I Partecke; C D Heidecke; M M Lerch
Journal:  Chirurg       Date:  2012-02       Impact factor: 0.955

3.  Frozen sectioning of the pancreatic cut surface during resection of intraductal papillary mucinous neoplasms of the pancreas is useful and reliable: a prospective evaluation.

Authors:  Anne Couvelard; Alain Sauvanet; Reza Kianmanesh; Pascal Hammel; Nathalie Colnot; Philippe Lévy; Philippe Ruszniewski; Pierre Bedossa; Jacques Belghiti
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

Review 4.  Precursors to pancreatic cancer.

Authors:  Ralph H Hruban; Anirban Maitra; Scott E Kern; Michael Goggins
Journal:  Gastroenterol Clin North Am       Date:  2007-12       Impact factor: 3.806

5.  An analysis of clinico-pathologic features of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Wenhui Lou; Dayong Jin; Dansong Wang; Xuefeng Xu; Tiantao Kuang; Xinyu Qin
Journal:  Front Med China       Date:  2007-02-01

6.  Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience.

Authors:  Marco Niedergethmann; Robert Grützmann; Ralf Hildenbrand; Dag Dittert; Niloufar Aramin; Melanie Franz; Frank Dobrowolski; Stefan Post; Hans-Detlev Saeger
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

7.  Pancreatic head resection with segmental duodenectomy for intraductal papillary mucinous tumors of the pancreas.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Yujiro Yokoyama; Masaru Sasaki; Masahiko Morifuji; Yasuo Hayashidani; Takeshi Sudo; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2004 Sep-Oct       Impact factor: 3.452

8.  Diagnostic evaluation of cystic pancreatic lesions.

Authors:  B C Visser; V R Muthusamy; B M Yeh; F V Coakley; L W Way
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

9.  Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms.

Authors:  Dirk Bausch; Mari Mino-Kenudson; Carlos Fernández-Del Castillo; Andrew L Warshaw; Kimberly A Kelly; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2009-09-17       Impact factor: 3.452

10.  Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Yasuo Hayashidani; Takeshi Sudo; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2007-03       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.